(Q87402141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Prostate cancer: treatment sequencing for CRPC--what do we know? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Axel Heidenreich

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Daniel Porres

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

4 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

189-190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Increased survival with enzalutamide in prostate cancer after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

A new trick of an old molecule: androgen receptor splice variants taking the stage?!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.36

31 March 2020

Identifiers

DOI

10.1038/NRUROL.2014.36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24595127%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference